MedTrace Logo

Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma

NCT00027508 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-02-24

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have malignant mesothelioma that cannot be removed by surgery.

Conditions

  • Malignant Mesothelioma

Interventions

DRUG

trabectedin

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • PharmaMar

    lead INDUSTRY

Principal Investigators

  • Lee M. Krug, MD · Memorial Sloan Kettering Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-07-31
Primary Completion
2002-02-28
Completion
2002-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00027508 on ClinicalTrials.gov